Probi AB PROB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 260.00
- Day Range
- SEK 248.00–260.00
- 52-Week Range
- SEK 171.50–319.00
- Bid/Ask
- SEK 249.00 / SEK 253.00
- Market Cap
- SEK 2.84 Bil
- Volume/Avg
- 373 / 580
Key Statistics
- Price/Earnings (Normalized)
- 204.86
- Price/Sales
- 4.61
- Dividend Yield (Trailing)
- 0.50%
- Dividend Yield (Forward)
- 0.50%
- Total Yield
- 0.50%
Company Profile
Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. Its research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 162
- Website
- https://www.probi.com
Comparables
Valuation
|
Metric
|
PROB
|
BIOG B
|
PEXIP
|
|---|---|---|---|
Price/Earnings (Normalized) | 204.86 | 29.45 | 57.99 |
Price/Book Value | 2.09 | 7.27 | 2.50 |
Price/Sales | 4.61 | 8.36 | 3.71 |
Price/Cash Flow | 33.89 | 24.45 | 21.13 |
Price/Earnings
PROB
BIOG B
PEXIP
Financial Strength
|
Metric
|
PROB
|
BIOG B
|
PEXIP
|
|---|---|---|---|
Quick Ratio | 4.51 | 4.58 | 1.79 |
Current Ratio | 6.04 | 6.49 | 1.83 |
Interest Coverage | 2.43 | 132.85 | −6.56 |
Quick Ratio
PROB
BIOG B
PEXIP
Profitability
|
Metric
|
PROB
|
BIOG B
|
PEXIP
|
|---|---|---|---|
Return on Assets (Normalized) | 0.88% | 17.97% | 2.44% |
Return on Equity (Normalized) | 0.96% | 20.83% | 3.17% |
Return on Invested Capital (Normalized) | 0.48% | 18.84% | 2.01% |
Return on Assets
PROB
BIOG B
PEXIP
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Bqqtwmzv | Fgd | $88.3 Bil | |||
| Merck KGaA ADR
MKKGY
| Scktsmsd | Yvgknm | $77.4 Bil | |||
| Haleon PLC ADR
HLN
| Hqnrhrx | Zmc | $47.3 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Rnpwbgn | Dnhyb | $19.0 Bil | |||
| Viatris Inc
VTRS
| Rjchhhmm | Hxzf | $13.9 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Jjfchzbx | Htzq | $13.4 Bil | |||
| Catalent Inc
CTLT
| Fybtkjc | Zcdyl | $10.9 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Xjmsvmkvf | Nnmxwxh | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Fwnmkhf | Dxm | $3.5 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Bwwzlwsg | Mxl | $2.5 Bil |
United States